Glifempa-Lin combines empagliflozin, an SGLT2 inhibitor, with linagliptin, a DPP-4 inhibitor.
Empagliflozin lowers blood glucose by increasing urinary glucose excretion, while linagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release.
Together, these complementary actions improve glycaemic control with a low risk of hypoglycaemia when used without insulin or sulfonylureas.
Uses
- Type 2 diabetes mellitus
Active Ingredients
- Empagliflozin 10mg
- Linagliptin 5mg
How to Take
- Take one tablet once daily, with or without food, exactly as prescribed.
Precautions
- Prescription-only medicine.
- Monitor kidney function and blood glucose regularly.
- Maintain adequate hydration.
- Inform your healthcare provider if symptoms of pancreatitis or urinary tract infections occur.
